The Analyst Verdict: Editas Medicine In The Eyes Of 4 Experts
Portfolio Pulse from Benzinga Insights
Over the past three months, four analysts have shared their insights on Editas Medicine (NASDAQ:EDIT), with opinions ranging from bullish to bearish. The average 12-month price target has decreased by 32.14% to $9.5. Analysts from Evercore ISI Group, Citigroup, Morgan Stanley, and Barclays have all lowered their price targets, reflecting a cautious outlook on the company's future performance. Financial indicators show challenges in revenue growth, net margin, ROE, and ROA, although the company maintains a low debt-to-equity ratio.
May 30, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Analysts have lowered their price targets for Editas Medicine, with the average 12-month target dropping by 32.14% to $9.5. Financial indicators show challenges in revenue growth, net margin, ROE, and ROA, although the company maintains a low debt-to-equity ratio.
The significant reduction in the average 12-month price target by analysts indicates a bearish outlook on Editas Medicine's future performance. The company's financial challenges, including a substantial decline in revenue growth and poor profitability metrics, further support this negative sentiment. However, the low debt-to-equity ratio is a positive aspect, suggesting conservative financial management.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100